glycogen phosphorylase inhibitor

Glycogen phosphorylase-IN-1 is a selective and potent inhibitor of human hepatic glycogen phosphorylase (hlGPa) with inhibitory effects on hlGPa activity and on hepatocyte glycogen-derived glucose production, and can be used in the study of type 2 diabetes mellitus and canine lupus.

AVE5688, an inhibitor of glycogen phosphorylase (GP), has IC₅₀ values of 430 nM and 915 nM, and Kd values of 170 nM and 530 nM for rmGPb and rmGPa, respectively. It is suitable for research on type 2 diabetes.

Uric acid is an important antioxidant that scavenges oxygen radicals and reactive oxygen species (such as singlet oxygen and peroxynitrite), inhibits lipid peroxidation, helps maintain stable blood pressure, and is the final product of purine metabolism. It is commonly used to induce hypertension models.

N6-Methyladenosine 5'-monophosphate disodium salt is a glycogen phosphorylase b activator and an inhibitor of adenylate kinase II.

BAY R3401 is an orally active inhibitor of glycogen phosphorylase, leading to irreversible and non-selective inhibition of liver glycogenolysis. It suppresses glycogen breakdown in hepatocytes with IC₅₀ values of 27.06 μM in HL-7702 cells and 52.83 μM in HepG2 cells. BAY R3401 is applicable for research in type 2 diabetes.

RMGPa-IN-1 (Compound 10C) is an inhibitor of rabbit muscle glycogen phosphorylase a (RMGPa), exhibiting an IC₅₀ value of 82.5 μM. This compound holds potential for research in diabetes.

Glycogen phosphorylase-IN-2 (compound 9C) is an inhibitor of glycogen phosphorylase, with a Ki value of 1.9 nM and an IC₅₀ value of 4 nM.

CP-316819 (GPi 819) is a potent inhibitor of glycogen phosphorylase (GPase) with hypoglycemic effects, inhibits huSMGPa and huLGPa, maintains neuronal activity during hypoglycemia, and can be used in the study of hyperglycemia.

CP-320626 is a highly efficient human liver glycogen phosphorylase (GP) inhibitor with cholesterol-lowering activity. It inhibits cholesterol biosynthesis by directly inhibiting CYP51 and can be used in type 2 diabetes research.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC₅₀ of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.

AVE 9423 is an allosteric glycogen phosphorylase inhibitor.

1,4-Dideoxy-1,4-Imino-D-Arabinitol Hydrochloride is a naturally occurring, polyhydroxylated pyrrolidine alkaloid that has been isolated and characterized from various plant species, including Arachniodes standishii and Angylocalyx boutiqueanus, 1,4-Dideoxy-1,4-Imino-D-Arabinitol Hydrochloride functions as a potent inhibitor of certain glycosidase enzymes due to its structural mimicry of monosaccharide substrates.

Ingliforib (CP 368296) is a novel glycogen phosphorylase inhibitor with antihyperglycemic and cardioprotective properties.

Morolic acid and moronic acid have shown sustained antidiabetic and antihyperglycemic action possibly mediated by an insulin sensitization with consequent changes of glucose, cholesterol and triglycerides, in part mediated by inhibition of 11β-HSD 1. Moro